TGFB1 and neoplasm: GARP, which is a type I transmembrane cell surface docking receptor for the SLC, cooperates with αV integrins (GARP/αV) to release active TGF-β from the surface of Tregs, B cells, NK cells, platelets, cancer-associated fibroblasts (CAFs) and tumor cells, thereby promoting immunosuppressive functions of the TME (14).